Technical Analysis for LQDA - Liquidia Technologies, Inc.

Grade Last Price % Change Price Change
grade F 8.17 -0.37% -0.03
LQDA closed down 0.37 percent on Wednesday, April 24, 2019, on 1.49 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: May 2

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical LQDA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -0.37%

Older signals for LQDA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Liquidia Technologies, Inc. (“Liquidia”) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. PRINT® is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia’s lead product candidate, LIQ861, currently being evaluated in a Phase 3 clinical trial (INSPIRE), is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has recently completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology.
Health Biopharmaceutical Life Sciences Pharmaceutical Pharmaceutical Industry Pain Medication Clinical Trial Pulmonary Arterial Hypertension Two River Treprostinil
Is LQDA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 38.46
52 Week Low 8.01
Average Volume 148,402
200-Day Moving Average 0.0
50-Day Moving Average 13.7702
20-Day Moving Average 10.039
10-Day Moving Average 9.276
Average True Range 0.9672
ADX 44.04
+DI 11.0066
-DI 30.0783
Chandelier Exit (Long, 3 ATRs ) 8.9984
Chandelier Exit (Short, 3 ATRs ) 10.9116
Upper Bollinger Band 11.9899
Lower Bollinger Band 8.0881
Percent B (%b) 0.02
BandWidth 38.866421
MACD Line -1.4645
MACD Signal Line -1.4461
MACD Histogram -0.0184
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.43
Resistance 3 (R3) 9.52 9.18 9.22
Resistance 2 (R2) 9.18 8.86 9.14 9.15
Resistance 1 (R1) 8.68 8.66 8.93 8.59 9.08
Pivot Point 8.34 8.34 8.47 8.30 8.34
Support 1 (S1) 7.84 8.02 8.09 7.75 7.26
Support 2 (S2) 7.50 7.82 7.46 7.19
Support 3 (S3) 7.00 7.50 7.12
Support 4 (S4) 6.91